KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $13.9 million.

  • AbCellera Biologics' Share-based Compensation fell 1904.57% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year decrease of 1553.57%. This contributed to the annual value of $67.6 million for FY2024, which is 529.42% up from last year.
  • Per AbCellera Biologics' latest filing, its Share-based Compensation stood at $13.9 million for Q3 2025, which was down 1904.57% from $14.2 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Share-based Compensation peaked at $17.8 million during Q2 2024, and registered a low of $5.4 million during Q1 2021.
  • In the last 5 years, AbCellera Biologics' Share-based Compensation had a median value of $14.2 million in 2025 and averaged $13.4 million.
  • In the last 5 years, AbCellera Biologics' Share-based Compensation surged by 129818.48% in 2021 and then plummeted by 2010.46% in 2025.
  • AbCellera Biologics' Share-based Compensation (Quarter) stood at $9.0 million in 2021, then skyrocketed by 47.41% to $13.3 million in 2022, then increased by 23.46% to $16.4 million in 2023, then dropped by 7.43% to $15.2 million in 2024, then decreased by 8.74% to $13.9 million in 2025.
  • Its Share-based Compensation stands at $13.9 million for Q3 2025, versus $14.2 million for Q2 2025 and $14.8 million for Q1 2025.